Nedaplatin
Trials 58 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 28 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01712919 Background | May 2010 → Mar 2014 | nasopharyngeal carcinoma | Jiangsu Cancer Institute & Hospital | Completed | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT06775275 Background | Sep 2024 → Dec 2025 overdue | non-small cell lung carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06424899 Background | May 2024 → May 2027 expected | non-small cell lung carcinoma | Zeng Jian | Recruiting | No outcome recorded |
| Phase 2 | NCT06231680 Background | Jan → Jun 2024 | carcinoma of esophagus, non-small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05624099 Background | Aug 2023 → Dec 2025 overdue | neoplasm of esophagus | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05872724 Background | Jan 2023 → Jan 2028 expected | cervical cancer | Suzhou Municipal Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05380271 Comparator | Jul → Dec 2022 | non-small cell lung carcinoma | Gang Wu | Unknown | No outcome recorded |
| Phase 2 | NCT04143984 Background | Jan 2021 → Dec 2025 | nasopharyngeal carcinoma | Shanghai Proton and Heavy Ion Center | Unknown | No outcome recorded |
| Phase 2 | NCT04421469 Background | Jun 2020 → Apr 2023 | nasopharyngeal carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04338620 Comparator | Apr 2020 → Nov 2023 | non-small cell lung carcinoma | Tang-Du Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04275687 Background | Mar 2020 → Feb 2025 | respiratory system cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03905317 Background | Mar 2019 → Feb 2022 | lung adenocarcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03904563 Background | Jan 2019 → Dec 2021 | lung adenocarcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT03649945 Comparator | Nov 2018 → Nov 2020 | esophageal cancer | First Affiliated Hospital of Guangxi Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT03659578 Background | Aug 2018 → Sep 2021 | non-small cell lung carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT03661567 Background | Aug 2018 → Sep 2021 | non-small cell lung carcinoma | Sun Yat-sen University | Terminated | No outcome recorded |
| Phase 2 | NCT03290820 Background | Jan 2018 → Sep 2024 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03101514 Background | Jan 2017 → Feb 2021 | head and neck cancer | First Affiliated Hospital of Harbin Medical University | Completed | No outcome recorded |
| Phase 2 | NCT02858206 Comparator | Jun 2016 → Nov 2019 | carcinoma of esophagus | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT02590133 Background | Jul 2015 → Dec 2018 | nasopharyngeal carcinoma | Yun-fei Xia | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03344068 Background | Jan 2018 → Dec 2020 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02777788 Comparator | Sep 2014 → Dec 2019 | cancer | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT06102395 Background | May 2023 → Apr 2027 expected | head and neck squamous cell carcinoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06190782 Background | Sep 2022 → Sep 2025 overdue | esophageal squamous cell carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT03731442 Background | Nov 2018 → Oct 2022 overdue | esophageal cancer | Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT03308552 Comparator | Dec 2017 → Aug 2020 | neoplasm of esophagus | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01951482 Comparator | Jan 2016 → Dec 2023 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02537925 Background | Jan 2014 → Dec 2016 | nasopharyngeal carcinoma | Changjie Huang | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 88 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nedaplatin | “Patients were randomly assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2, and platinum [cisplatin, 75 mg/m2; carboplatin, area...” PMID 37535377 ↗ Oct 202386“pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle for four to six cycles, followed by pemetrexed maintenance...” NCT01951482 ↗ “Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin:...” NCT05880082 ↗ “Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.” NCT00197444 ↗ “Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;” NCT06231680 ↗ “All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .” NCT03663764 ↗ “paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.” NCT06775275 ↗ “Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2.” NCT03529279 ↗ “Chemotherapy with cisplatin or nedaplatin (both 80-100mg/m2, 21 day per cycle, 1-3 cycles) is used or not concurrent with radiotherapy.” NCT03101514 ↗ “administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4.” NCT04666090 ↗ “other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.” NCT06190782 ↗ “Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.” NCT03900117 ↗ “Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.” NCT02573506 ↗ “Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.” NCT03659578 ↗ “For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.” NCT04275687 ↗ “Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks” NCT03328234 ↗ “Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks” NCT03308552 ↗ “The experimental group received 4-course chemotherapy of docetaxel combined with nedaplatin” NCT04174079 ↗ “Nedaplatin 75mg/m2 was added to 500ml 0.9% sodium chloride injection, once every 3 weeks.” NCT06055153 ↗ “Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.” NCT03290820 ↗ “Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy” NCT03673657 ↗ “Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.” NCT03344068 ↗ “1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.” NCT04421469 ↗ “Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.” NCT05872724 ↗ “weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation” NCT03661567 ↗ “Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks” NCT04275986 ↗ “weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation” NCT03904563 ↗ “weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation” NCT03905317 ↗ “weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation” NCT03006575 ↗ “albumin paclitaxel 130 mg/m2, Days 1 and 8 + nedaplatin 80 mg/m2, Day 1” NCT06015035 ↗ “Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.” NCT04143984 ↗ “Platinum drug must be one of cisplatin, carboplatin or nedaplatin;” NCT06424899 ↗ “Cisplatin, carboplatin, nedaplatin and other platinum drugs” NCT05624099 ↗ “Only infusion chemotherapy (THP + Nedaplatin + Letitrexed)” NCT05380271 ↗ “Alternatively, Nedaplatin: 75 mg/m², Day 2, Q3W.” NCT07015489 ↗ “nedaplatin 10 mg / m2 twice a week for 0.5 hours” NCT04524299 ↗ “Pemetrexed (D1) + nedaplatin (D1) chemotherapy” NCT01951469 ↗ “for nedaplatin 50mg/m2, d1-2, every 3 weeks” NCT03731442 ↗ “Docetaxel 75mg/m2 +Nedaplatin 75mg/m2” NCT01137123 ↗ “nedaplatin 100mg/m2, on the 1st day;” NCT05351762 ↗ “Nedaplatin” NCT05880082 ↗ |
| Known as | Aqupla | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137685 ↗ |
| Known as | CDGP | “Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.” NCT00197444 ↗ |
| Known as | cis-diammine-glycolatoplatinum | “We evaluated the efficacy and the toxicity of a novel regimen of daily low-dose nedaplatin (cis-diammine-glycolatoplatinum) and continuous infusion of 5-fluorouracil (5-FU)...” PMID 19930599 ↗ Nov 2009 |
| Known as | NDP | “Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle” NCT02835404 ↗ |
| Known as | Nedaplatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137685 ↗ |
| Known as | Nedaplatino | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137685 ↗ |
| Known as | NSC-375101D | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137685 ↗ |
| Modality | Small molecule | “Nedaplatin is a second-generation platinum compound” NCT02088515 ↗ |
| Route | Intravenous | “IV drip on day 1 of each 21 day cycle” NCT01137123 ↗ |